|
Research on Pegasys and PegIntron
2007-2004
2008
Dec-Nov 2007
How Effective Is Pegylated Interferon
plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
Depression Due to Treatment with
Pegylated Interferon plus Ribavirin May Be Under-diagnosed by
Clinicians
Pegylated interferon alfa and ribavirin for 14
versus 24 weeks in patients with hepatitis C virus genotype 2 or 3
and rapid virological response -
Prophylaxis with Pegylated Interferon
Alfa-2a (Pegasys) plus Ribavirin vs No Prophylaxis after Liver
Transplantation
Is Pegylated Interferon Alfa-2a (Pegasys)
plus Ribavirin Superior to High-dose Consensus Interferon (Infergen)
plus Ribavirin?
Induction with High-dose Pegylated Interferon
alfa-2a (Pegasys) Is More Effective than Standard Dosing for
Achieving Rapid and Early Virological Response: The CHARIOT Study
PEGINTRON(TM) and REBETOL(R) Approved in
European Union for Retreating Hepatitis C Patients Who Failed
Previous Pegylated or Non-Pegylated Interferon Therapy
-
Assessment of HCV RNA at Week 4 and Week 12
Optimizes Prediction of Treatment Outcomes in HCV Patients Treated
with Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin
Viral Kinetics Can Quickly Predict Sustained
Virological Response in Hepatitis C Patients with Normal ALT Treated
with PegIntron plus Ribavirin
European Drug Regulators Approve PegIntron
plus Rebetol for Retreating HCV Patients Who Failed Prior Therapy
HALT-C Trial Shows Minimal Long-term Benefit
of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in
Patients with Chronic Hepatitis C
Long-term, Low-Dose Treatment with Pegylated
Interferon Alfa-2b (PegIntron) Monotherapy Leads to a Reduction in
Fibrosis and Inflammatory Scores in Prior Non-responders
Rapid Virological Response at Week 4 Is the
Best Predictor of Treatment Outcome in Patients With Chronic
Hepatitis C: A Multivariate Analysis
Interim Data Show Nitazoxanide (Alinia)
Improves Anti-HCV Activity When Added to Pegylated Interferon plus
Ribavirin
Response-guided therapy in a prospective trial of
peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV
genotype 1 or 4
HCV patients with genotype 2 or 3 who do not achieve a
rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS)
and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR
patients from the ACCELERATE study
:
High rates of sustained virologic response (SVR) in
patients >50 years infected with HCV genotype 1 with positive prognostic
factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)
Differentiation of early virologic response (EVR) into
RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise
prediction of SVR in HCV genotype 1 patients treated with peginterferon
alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS)
Outcomes in HIV-HCV co-infected genotype 1 patients
treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200
mg/day: predictions based on generalized additive models
High chance of cure in HCV genotype 1 patients with a
low viral load achieving an RVR treated for 24 weeks with pegylated
interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective,
randomized, controlled study comparing 24 & 48 weeks of treatment
-
The DIRECT Trial (Daily-Dose
Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment
of non-responders to previous pegylated interferon plus ribavirin: sustained
virologic response data
Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV)
in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final
efficacy and safety outcomes of the REPEAT study
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
in Non-responders to Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin:
Final Results of the REPEAT Trial
Experimental Roche Polymerase Inhibitor R1626 Shows
Robust Synergistic Effect in Combination with Pegylated Interferon with or
without Ribavirin
Final Results of the Canadian Pegylated Interferon
alfa-2b (PegIntron) Prospective Optimal Weight-based Dosing Response (POWeR)
Study -
Assessment of Viral Kinetics Helps Predict Response to
Treatment with Pegylated Interferon Alfa plus Ribavirin in Chronic Hepatitis
C Patients
Highly Sensitive HCV RNA Tests Required to Evaluate
Treatment Response and Relapse Rates and to Create Individualized Treatment
Strategies for Hepatitis C Patients
Early Treatment Is Indicated for Patients with Chronic
Hepatitis C Regardless of Body Weight
Rapid and early virological response rates are
increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard
ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety
analysis of the induction phase of the CHARIOT study
-
Evaluation of Viral Variants During a Phase 2 Study
(PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in
Treatment-naïve HCV Genotype 1-Infected Patients
Long-Term, Low-Dose Treatment With Pegylated
Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and
Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With
Fibrosis or Cirrhosis
Twice vs Once Weekly Dosing of Peginterferon Alfa 2a
in Chronic HCV Genotype 1 Infection: Analysis of Early Viral Kinetics
Significant New Data on Roche's PEGASYS(R) and
Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD
Meeting
FROM THE ADVOCATE
Pegasys
o
LB1. Prolonged Antiviral Therapy With Peginterferon to Prevent
Complications of Advanced Liver Disease Associated With Hepatitis C:
Results of the Hepatitis C Antiviral Long-term Treatment against
Cirrhosis (HALT-C) Trial
o
LB4. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior
non-responders to pegylated interferon alfa-2b (12KD)/RBV: final
efficacy and safety outcomes of the REPEAT study
o
25. Prophylactic
Peginterferon Alfa-2a/Ribavirin vs No Prophylaxis Following Orthotopic
Liver Transplantation (OLT) for Hepatitis C: 24-Week Virologic and
Safety Responses
o
54. Rapid and early virological response rates are increased with 12
week 360 µg/wk peginterferon alfa-2a (40KD) and standard ribavirin in
HCV genotype 1 treatment naive patients: efficacy and safety analysis of
the induction phase of the CHARIOT study
o
164. HCV Patients with Genotype 2 or 3 Who Do Not Achieve a Rapid
Virologic Response (RVR) with Peginterferon alfa-2a (40KD)(PEGASYS®) and
Ribavirin (COPEGUS®) Are Not Easy to Treat: An analysis of non-RVR
patients from the ACCELERATE study
o
180. Sustained Virologic Response rates with albinterferon alfa-2b plus
ribavirin treatment in IFN-naïve, chronic hepatitis C genotype 1
patients
o
233. An Open Label, Comparative, Multicenter Study Of Peginterferon
Alfa-2a Plus Ribavirin in The Treatment Of Patients With Chronic
Hepatitis C/Hepatitis B Co-Infection Versus Those With Chronic Hepatitis
C
o
234. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients
responding to Peg-interferon alfa-2a and ribavirin
(updated
November 3,
2007)
o
235. Randomized, double-blind, placebo-controlled trial of Peginterferon
alfa-2a (40kD) and ribavirin with and without 400 mg amantadine-sulphate
for 48 weeks in treatment naïve HCV genotype 1-infected patients
o
237. Twice vs Once Weekly Dosing of Peginterferon Alfa 2a in Chronic HCV
Genotype 1 Infection: Analysis of Early Viral Kinetics
(updated
November 3,
2007)
o
245. Efficacy and Safety of Escitalopram for the Prevention of
Depressive Episodes Induced by Peg-Interferon Alpha2a and Ribavirin in
Chronic Hepatitis C Patients. A Double-Blind, Randomized,
Placebo-Controlled Trial.
(updated
November 3,
2007)
o
251. Response to high ribavirin dose in combination with peg-INF alfa-2a
for treatment of HCV genotype 1 previous non-responders
(updated
November 3,
2007)
o
271. Predictors of Response to Pegylated Interferon-α2A and Ribavirin in
a Cohort of Patients Infected with the Same Strain of HCV: The O’Brien
Project
o
276. Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD)
(PEG) and Ribavirin (RBV) in naïve patients with HIV-HCV co-infection in
the real-life setting in Germany
(updated
November 4,
2007)
o
285. Efficacy of peginterferon alfa-2a and ribavirin in 2101 patients
with HCV infection in real-life clinical practice: results of the French
Hepatys study
o
310. Effects of systematic nurse-provided therapeutic education on
adherence and efficiency of PEG-Interferon-a2a(Pegasys®)-ribavirin
treatment in chronic hepatitis C (Pegobs Protocol)
o
322. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis
C, genotype 2 & 3: viral kinetics, efficacy and safety
o
321. High rates of sustained virological response (SVR) in patients >50
years infected with HCV genotype 1 with positive prognostic factors
treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)
(updated
November 4,
2007)
o
327. Comparison of efficacy of treatment with peginterferon alfa-2a plus
ribavirin vs peginterferon alfa-2b plus ribavirin among patients
chronically infected with non 2/3 HCV genotypes with low and high
pretreatment viral load
o
328. PEG Interferon ALFA-2A Monotherapy in Dialysis Patients Infected
with Hepatitis C Virus
(updated
November 3,
2007)
o
334. Eight-week oral administration of meloxicam, a COX-II specific
non-steroidal anti-inflammatory drug, prevents dose reduction of
pegylated interferon alfa-2a in the treatment of chronic hepatitis C
o
337. PEG-IFN alfa-2A plus Ribavirin is Superior Compared to High Dose
Consensus Interferon (CIFN) and Ribavirin in the Treatment of Patients
with Chronic Hepatitis C
(updated
November 4,
2007)
o
352. The depression induced by peginterferon alfa-2a and ribavirin in
the treatment of chronic hepatitis C is under-diagnosed by the clinician
o
1301. Response-guided therapy in a prospective trial of peginterferon
alfa-2a (40KD)/ribavirin treatment in patients with genotypes 1 or 4
(updated
November 3,
2007)
o
1305. Association of Pre-Treatment and On-Treatment Factors with Rapid
Virologic Response in HCV Genotype 1 Infected Patients Treated with
PegIFNα-2a/RBV
o
1309. Final Results of Patients Receiving
Peg-Interferon-Alfa-2a (Peg-IFN) and Ribavirin (RBV) After a 14-Day
Study of the Hepatitis C Protease Inhibitor Telaprevir (VX-950), With
Peg-IFN
o
1308. Differentiation of early virologic response (EVR) into RVR,
complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise
prediction of SVR in HCV genotype 1 patients treated with peginterferon
alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)
o
1310. Retreatment of HCV Genotype 1 Relapse Patients to Peginterferon/Ribavirin
Therapy with an extended Treatment Regimen of 72 weeks with Consensus
Interferon/Ribavirin versus Peginterferon alpha/Ribavirin
o
1316. High chance of cure in HCV genotype 1 patients with a low viral
load achieving an RVR treated for 24 wks with peginterferon alfa-2a (PEGASYS®)
plus ribavirin (COPEGUS®): Prospective, randomized, controlled study
comparing 24 and 48 weeks of treatment
o
1329. Viral Kinetics Of HCV Genotype 4 During Pegylated Interferon Alpha
2a –Ribavirin Therapy
o
1303. Peginterferon ALFA-2A and Ribavirin for 12 or 24 Weeks in Patients
With HCV Genotype 2/3: The Nordynamic Trial
o
1327. Comparison of peginterferon alfa-2a and ribavirin for 12 or 24
weeks in patients with HCV genotype 2 or 3: the CLEO trial
(updated
November 6,
2007)
·
PEG-Intron
o
51. Sustained Virologic Response with albinterferon alfa-2b/ribavirin
treatment in prior interferon therapy non-responders
o
238. Sustained Virological Response Is Associated with Eradication of
Hepatitis C Virus and Decrease in anti-HCV Titer in Patients Treated for
Chronic Hepatitis C with Interferon alpha 2b or Pegylated Interferon
alpha-2b+ribavirin.
o
246. Response to Peginterferon alfa-2b + Ribavirin Combination Therapy
in Genotype 2 and 3 Patients With Poor Baseline Prognostic Factors:
Results of the Canadian POWeR Program
o
254. Final Results of the Canadian POWeR (Peginterferon alfa-2b
Prospective Optimal Weight-based Dosing Response) Program. Sustained
Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b +
Ribavirin in a Large, Mixed Community and Academic Observational Study
(updated
November 3,
2007)
o
261. Relapse rates among HCV Genotype 1 early virological responders in
a retrospective community-based cohort of patients treated with PEGETRON®
in British Columbia, Canada
(updated
November 3,
2007)
o
262. Viral and STAT kinetics in patients with chronic hepatitis C
treated with pegylated interferon a-2b plus ribavirin
(updated
November 3,
2007)
o
272. Time to HCV RNA Negativation in Hepatitis C Virus (HCV) Type
1-Infection During PEG-Interferon-alpha-2B plus Ribavirin Therapy:
Differences in Relation to the Assay Sensitivity (Indiv-1 Study Group)
(updated
November 3,
2007)
o
279. Treatment of Hemodialysis (HD) Patients With Chronic Hepatitis C (CHC)
Using an Escalating Dose Regimen of Pegylated Interferon (PEG-IFN)
alfa-2b
o
297. Pegylated Interferon alfa-2b plus Ribavirin reduces insulin
resistance and improves glucose metabolism in patients with chronic
hepatitis C
o
302. Consistency of Sustained Virologic Response (SVR) Across Weight
Categories: Results From the Canadian POWeR (Peginterferon alfa-2b
Prospective Optimal Weight-based Dosing Response) Program
o
309. Impact of reducing peginterferon alfa-2b and ribavirin on early
viral response in genotype 1 infected patients with chronic hepatitis C
o
312. Viral kinetics can quickly predict sustained virological response
in HCV patients with normal ALT treated with pegylated ifn α2b and
ribavirin: a prospective study
o
318. The level of pretreatment HCV core antigen is a new and useful
predictor for the efficacy of peginterferon alpha-2b and ribavirin in
patients with chronic hepatitis C
o
325. Patient education improves adherence to peginterferon α-2b and
ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A
prospective, real-life study (CHEOBS Study)
o
326. Peginterferon alfa-2b and ribavirin treatment of patients with
chronic hepatitis C and normal versus elevated aminotransferase levels –
final results of a prospective open trial
(updated
November 3,
2007)
o
336. Treatment and outcome of genotype 4 chronic hepatitis C patients
with PegInterferon alfa 2b and Ribavirin in the clinical setting in
Germany
(updated
November 3,
2007)
o
353. Combination therapy with pegylated interferon alfa-2b and ribavirin
for patients with chronic hepatitis C and normal aminotransferase levels
(updated
November 4,
2007)
o
1311. Long-term Low Dose Treatment with Pegylated Interferon alpha 2b
leads to a significant Reduction in Fibrosis and Inflammatory Score in
Chronic Hepatitis C Nonresponder Patients with Fibrosis or Cirrhosis
(updated November 3, 2007)
o
1315. Favorable quality of life (QoL) with albinterferon alfa-2b plus
ribavirin in genotype 1, IFN-naïve, chronic hepatitis C (CHC) patients
o
1322. Tolerability of Low-Dose Peginterferon alfa-2b in Hepatitis C
Patients with Cirrhosis: Results from the CoPilot Trial
·
Predictors of Treatment Response
o
249. Pretreatment insulin sensitivity contributes to the treatment
response to peginterferon plus ribavirin combination therapy for
patients with chronic hepatitis C
(updated
November 3,
2007)
o
282. Clinical Relevance of Rapid Virological Response (RVR) in
Decompensated HCV-Related Cirrhosis Treated with PEG-Interferon and
Ribavirin
o
284. Iron Depletion and Response to Interferon in Chronic Hepatitis C (HCV)
: A Meta-Analysis
(updated
November 3,
2007)
o
290. Predictors of Sustained Virological Response to Interferon-based
Treatment in Hemodialysis Patients with Chronic Hepatitis C Virus
Infection - a Patient Level Meta-analysis
o
298. Whole-body, not only liver, insulin sensitivity is strongly
associated with an early and sustained virologic response to
peginterferon plus ribavirin treatment in patients with chronic
hepatitis C genotype 1b and high viral load
o
301. The Impact Of Steatosis And Steatohepatitis On The Response To
Treatment In Patients With Chronic Hepatitis C Infection
o
303. Rapid Virological Response at Week 4 is the Best Predictor of
Treatment Outcome in Patients with Chronic Hepatitis C: A Multivariate
Analysis
(updated November 3, 2007)
o
304. Assessment of Both Virological Response at Week 4 and at Week 12
Optimizes Prediction of Treatment Outcome in Patients with Chronic
Hepatitis C Treated with Peginterferon alfa-2B Plus Ribavirin
(updated
November 3,
2007)
o
305. Predictability of Response: Positive and Negative Predictive Values
of Rapid and Early Virologic Responses to Peginterferon alfa-2b and
Ribavirin in the Treatment of Chronic Hepatitis C
o
308. High predictive value of early viral kinetics in peginterferon plus
ribavirin combination therapy of genotype 1 infected patients with
chronic hepatitis C
o
320. Systemic Factors Associated with Virologic Nonresponse to
Peginterferon/Ribavirin Retreatment of Chronic Hepatitis C
o
340. Factors Impacting SVR in HCV Genotype 1 Patients with EVR and Week
24 Negativity
(updated
November 4,
2007)
o
349. Ultra Rapid Virologic Response Predicts Sustained Virologic
Response in HCV Infected Patients with Genotype 3 and High Viral Load:
The Get-C Study
o
354. The Role of Steatosis and Diabetes as a Predictor of Treatment
Response to Interferon Based Therapies in Latino Americans with Chronic
Hepatitis C
·
Side
Effects
o
258. Assessment of the impact of psychiatric disorders on safety,
compliance, and sustained virological response after hepatitis C
treatment (CHEOBS)
o
316. The cerebral metabolic and cognitive effects of Pegylated
Interferon (PIFN) and hepatitis C viral (HCV) clearance
o
330. GM-CSF May Modulate the Response to Therapeutic IFN-α in Chronic
Hepatitis C Virus (HCV) Infection
(updated
November 4,
2007)
o
351. Incidence and management of psychiatric disturbance in hepatitis C
patients treated outside of sponsored research protocols with
peginterferon and ribavirin
o
352. The depression induced by peginterferon alfa-2a and ribavirin in
the treatment of chronic hepatitis C is under-diagnosed by the clinician
(updated
November 4,
2007)
·
Side
Effect Management
o
260. Danazol Increases the Platelets Count in Thrombo-Cytopenic Patients
with Chronic Hepatitis C and Liver Cirrhosis Treated With Peg-Interferon
Alfa 2a and Ribavirin
(updated
November
HCV Advocate’s AASLD Conference coverage
HIV and Hepatitis.com Coverage of the
58th Annual
Meeting of the American Association
for the Study of Liver Diseases (AASLD 2007)
November 2-6, 2007, Boston, MA
Oct 2007
Significant New Data on Roche's PEGASYS(R) and
Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Weight-based Dosing Of Ribavirin Improves Outcomes For
Patients With Hepatitis C
Weight-based Ribavirin Is Superior to the Standard
Fixed Dose in Combination with Pegylated Interferon for Treatment of
Genotype 1 Hepatitis C
-
Some Patients with Genotype 1 Chronic Hepatitis C May
Benefit from Prolonged Treatment with Pegylated Interferon plus Ribavirin
Pharmasset Initiates Phase 1 Dose-ranging Study of
R7128 plus Pegasys plus Copegus in Genotype 1, Treatment-naive Hepatitis C
Patients
FDA Safety Changes: Copegus, Intron A
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination
Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Sudden hearing loss associated with peginterferon and
ribavirin combination therapy during hepatitis
Sept-July 2007
Roche
Launches Another Large Study With PEGASYS Plus COPEGUS
Patients with Depression prior to Hepatitis C
Treatment Are Half as Likely to Achieve Sustained Virological Response
Prolonged Interferon Therapy May Prevent Progression
of Hepatitis C to Cancer
Two Recent Articles Focus on the Use of Telaprevir
(VX-950) plus Pegylated Interferon Alfa-2a (Pegasys) in Patients with
Chronic Hepatitis C
Use of Epoetin to Manage Anemia in Chronic Hepatitis C
Patients Treated with Pegylated Interferon plus Ribavirin
Peginterferon Alfa-2b (PegIntron) Linked to Risk for
Potentially Fatal Psychiatry
HCV Drug Pipeline
DDW 2007 Highlights:
Part 2
DDW 2007 Highlights
Part 1
Types of Interferon and How They Work
Interferon and Ribavirin
Importance of Adequate Ribavirin
Schering Plough Ends Celgosivir Deal
Studies Suggest Ribavirin Does Not Work by Causing
Excessive HCV Mutation
Interferon-based treatment of chronic hepatitis C.
72-week Treatment with Pegylated Interferon plus
Ribavirin Can Produce Sustained Virological Response in Some Prior Relapsers
Roche's Hepatitis C drug Pegasys patent challenged
-
Treatment of chronic hepatitis C virus genotype 1 with
peginterferon, ribavirin, and
epoetin alpha.
June 2007
HCV Can Be Cured
Treatment Duration and Histological Response to
Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs
better than 24 weeks
Safety and Tolerability of Peginterferon Alfa-2a Plus
Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon
Alfa-2b Plus Ribavirin -
Does Attainment of Sustained Virologic Response (SVR)
from Treatment of HCV Constitute a Cure?
A Follow-up Week 12 Viral Count Is Useful in
Predicting SVR and Is 100% Accurate in Patients without Cirrhosis
Asians with Genotype 1 HCV Respond as Well as Whites
to Interferon-based Therapy
Treatment of Chronic Hepatitis C in Older Patients
Both Pegasys/Ribavirin and PegIntron/Ribavirin
Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3
Patients
May 2007
Low-Dose PegIFN Maintenance Therapy Successful
HCV-796 Shows Antiviral Activity in Combination with
Pegylated Interferon
Response to PegIntron/ribavirin Leads to Stabilization
of Fibrosis in Liver Transplant Recipients
PegIntron + 2 HCV Nucleosides Show Synergy
-
April 2007
NATP
coverage of:
Does SVR after Treatment with Pegasys/ribavirin
Constitute a Cure for Chronic Hepatitis C?
14 Weeks of Treatment with PegIntron plus Ribavirin Is
Non-inferior to 24 Weeks in Rapid Responders with HCV Genotype 2 or 3
Pegylated Interferon plus Ribavirin in Patients with
HBV-HCV Dual Infection
Past Psychiatric Disorders Do Not Reduce Hepatitis C
Treatment Effectiveness in Genotype 2/3 Patients
Schering’s Experimental Oral HCV Protease Inhibitor
Boceprevir Appears Safe in Patients with Varying Degrees of Liver Impairment
-March 2007
Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C
Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R)
(ribavirin) Trial -
Procrit/Epogen FDA Safety Warning
Reasons
Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer
Treatment: Do
They Alter Their Decision with Time?
Improved Outcomes After SVR, Interferon Therapy
Pegylated Interferon plus Ribavirin Failure: Is
Re-treatment an Option?
PEGASYS(R) Gets European Approval for a Shorter Treatment Duration for Some
Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy
Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During
Retreatment in Patients With Chronic Hepatitis C (HALT-C Study)
-
Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients
Completing Peginterferon Alfa-2a/Ribavirin Treatment
-
Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both
Wild-Type and Resistant Hepatitis C Virus
Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients
Completing Peginterferon Alfa-2a/Ribavirin Treatment
-
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and
decompensated cirrhosis: A controlled study
-
Dec 2006
HCV Continues to Replicate in the Livers of Patients
with Sustained Response to Therapy
Report of 6 Cases of Complete HCV Remission
in Prior Non-Responders Treated with Pegylated Interferon Plus Ribavirin
Plus Thalidomide
Treatment of Hepatitis C in Patients with Advanced
Fibrosis or Cirrhosis
Impact and Management of Insulin Resistance in
Patients with Hepatitis C
Nov 2006
PegIntron plus Ribavirin
Coverage of 57th Annual Meeting
of the American Association for the Study of Liver Disease
Oct 27-31,2006, Boston MA
11/03/06
Pegasys plus Ribavirin
11/03/06
Treatment Extension to 72 Weeks of PegIntron plus
Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow
Responders with Genotype 1 11/03/06
HCV RNA Negativity after 12 Weeks of Therapy Is the
Best Predictor of SVR in Re-Treatment of Non-Responders: The EPIC3
Program 11/03/06
Baseline HCV RNA of 400,000 Best Predicts SVR and
Relapse Rates in Patients Treated with Pegasys plus Ribavirin
11/03/06
In ACCELERATE Trial, Highest SVR Seen in
Patients Who Received the Longest Duration of Therapy with Pegasys and the
Highest Mean Dose of Ribavirin Based on Body Weight
11/03/06
Sustained Virological Response
to PegIntron Plus Ribavirin in Asian and Hispanic Patients
11/03/06
October 2006
4-Week Response to Anti-HCV Treatment Predicts Outcome
Baseline viral load (400,000 IU/mL) as a predictor of
SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS)
in HCV/HIV Coinfected in Apricot Study
Spleen Removal Can Help Hepatitis C Patients
with Cirrhosis Tolerate Treatment
16-week Treatment May Be Adequate for Genotype 2
Hepatitis C Patients
Hepatitis C virus therapies -
Treating viral hepatitis C: efficacy, side effects, and complications
-
Cannabis use improves retention and virological outcomes in patients treated
for hepatitis C
28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With
PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates
Robust Antiviral Effects
Aug-July 2006
DDW 2006: Conference Highlights – Part 2
72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA
is Detectable at Week 4 -
Pegylated Interferon Plus Ribavirin Therapy in
Patients with HCV Recurrence after Liver Transplantation
Thyroid Dysfunction in Chronic
Hepatitis C Patients Treated with Interferon/Ribavirin
Relation between LDL Cholesterol Levels and Hepatitis
C Treatment Outcomes
Comparison of Pegasys vs Peg-Intron for
Treatment of Chronic Hepatitis C
Tolerability and Efficacy of Pegasys/Ribavirin
in Black Patients with Hepatitis C
New HCV Antivirals and Drug Resistance
Pegasys/RBV in
African-Americans -
Efficacy of Low-dose Peg-Intron
Pharmacokinetics and Antiviral Activity of Pegasys vs
Peg-Intron
Retreatment and Long-Term Follow-Up of Nonresponders
Sustained Virological Response (SVR) Rates and
Durability in a Clinical Setting
Statins active Against HCV, Especially When Combined
with Interferon
Genetic Variation Influences HCV Treatment Response,
Side Effects, and Disease Progression
Impact of Obesity on Hepatitis C and Treatment of HCV
June 2006
HCV is Detected in Liver of HCV Antibody-Positive But HCV RNA Negative
Patients, so don't assume HCV has been cleared if viral load is undetectable
-
3 New Combination Therapies
Promising Data on Consensus Interferon Retreatment of
Relapsers and Non-Responders
CPG 10101: Promising Data at 12 Weeks in Prior
Relapsers
Factors Influencing Treatment Response in WIN-R Trial
Predictors of Sustained Response to Peg-Intron or
Pegasys Plus Ribavirin
S1923 – The influence of cigarette smoking on response to treatment with
pegylated interferon alfa-2b and ribavirin in patients with chronic
hepatitis C
Abstract T1814 – A randomized trial comparing Short Course versus Standard
Treatment with non-pegylated interferon α and ribavirin in patients with
Chronic Hepatitis C Genotype 3 Virus Infection.
Abstract T1820 – Peginterferon Alfa-2a (40KD) (PEGASYS®) Plus Ribavirin (COPEGUS®)
for HCV Genotype 1 Patients: Predicting Sustained Virological Response (SVR)
Rates and Anemia
Hepatitis C: Current Standards of Care and Future
Perspectives
May 2006
Duration of Peginterferon Therapy in Acute Hepatitis C
Factors That Predict a Rapid Virological Response at
Week 4 and a Sustained Virological Response at Week 24
Feb 2006
Valopicitabine Dosed in Combination with Pegylated
Interferon Alfa-2a (Pegasys) Leads to Rapid Virologic Response in 93 percent
of Genotype 1 Hepatitis C Patients
FDA Grants Fast Track Review to Schering-Plough's New
Oral HCV Protease Inhibitor SCH 503034
In Whom, When, How, and with What Therapy to Treat
Acute Hepatitis C?
Jan 2006
Paul Marotta, MD, FRCPC, discusses the issue of flat-dosed vs weight-based
dosing regimens in the treatment of patients with hepatitis C.
HealthWise: To Treat or not to Treat — That is the
Question
24 Weeks Treatment with Peginterferon Alfa-2b (PegIntron)
plus Ribavirin Is Efficacious in Patients with Chronic HCV Genotype 1 and
Low Pretreatment HCV RNA Levels
Dec 2005
Learning about HCV in
2005
Predicting SVR/Nonresponse at weeks 1, 4, 12 with
Pegasys/RBV
Peginterferon-A-2a (40KD) and Ribavirin for
16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Page Two
Phase I Study New Hep C Drug for Peg/RBV Nonresponders
Peginterferon
Alfa-2b Plus Ribavirin Elicits Sustained Response in Decompensated HCV
Patients
Aug 10 2005
Predicting SVR: 12 Better than 4 Week Early Viral
Response
"Predicting sustained virological
responses in chronic hepatitis C patients treated with peginterferon alfa-2a
(40KD)/ribavirin"
June 09 2005
Peginterferon
Alfa-2b (PegIntron) and Ribavirin for Chronic HCV Patients Who Relapsed or
Were Non-responsive to Interferon/Ribavirin
June 04 2005
|
